Changes in Donor‐Derived Cell‐Free DNA Before and After Rejection and De Novo DSA Detection in Primary and Repeat Kidney Transplant Recipients
Open Access
- 5 November 2024
- journal article
- research article
- Published by Wiley in Clinical Transplantation
- Vol. 38 (11) , e70019
Abstract
Background: Serial monitoring of dd‐cfDNA and change from baseline can provide meaningful information beyond absolute thresholds. We describe dd‐cfDNA trajectories from the baseline before and after acute rejection (AR) and de novo donor‐specific antibodies (dnDSA) detection in kidney transplant recipients (KTRs).Methods: We included KTR from 02/2019 to 03/2022 with serial dd‐cfDNA. The primary analysis compared the time‐varying change in dd‐cfDNA from baseline in KTR first AR on biopsy [AR] to patients with no‐AR on biopsy [no‐AR].Results: 151 KTR were analyzed (AR = 56 KTR, no‐AR = 95 KTRs). In the AR group, dd‐cfDNA rose ahead of diagnosis: median rise from baseline was 75% at −3 months, 32% at −2 months, and 325% at −1 month before biopsy. At the time of biopsy, the median rise in dd‐cfDNA from baseline was 291% (IQR [interquartile range] 88%–1081%) in AR and 17% (IQR 0%– 194%) in no‐AR (p < 0.0001). Following treatment, dd‐cfDNA values fell in the AR group with a median change from baseline of 94.7% at +1 month, 10.5% at +2 months, and 0% at +3 months. These trajectories were not observed in the no‐AR group. Similarly, there were no significant differences in eGFR (estimated glomerular filtration rate) trajectories between the two groups. The median change from baseline to dnDSA detection was 141% (IQR 112%–574%). In KTRs with persistent rejection, median dd‐cfDNA was 0.95% (IQR 0.44–1.8) compared to 0.19% (IQR 0.12–0.31) in subjects with no rejection on follow‐up (p < 0.001).Conclusion: The significant changes from baseline observed before and after AR show how serial monitoring enhances dd‐cfDNA utility and allows for earlier identification of evolving injury and monitoring treatment response.Keywords
Funding Information
- CareDx
This publication has 28 references indexed in Scilit:
- Cell-free DNA for the detection of kidney allograft rejectionNature Medicine, 2024
- Clinical outcomes from the Assessing Donor-derived cell-free DNA Monitoring Insights of kidney Allografts with Longitudinal surveillance (ADMIRAL) studyKidney International, 2022
- Correlation of Donor-derived Cell-free DNA With Histology and Molecular Diagnoses of Kidney Transplant BiopsiesTransplantation, 2021
- Use of Donor-Derived Cell-Free DNA for Assessment of Allograft Injury in Kidney Transplant Recipients During the Time of the Coronavirus Disease 2019 PandemicTransplantation Proceedings, 2020
- Analytical Validation of a Single-nucleotide Polymorphism-based Donor-derived Cell-free DNA Assay for Detecting Rejection in Kidney Transplant PatientsTransplantation, 2019
- Subclinical Antibody-mediated Rejection After Kidney Transplantation: Treatment OutcomesTransplantation, 2019
- Donor-derived Cell-free DNA Identifies Antibody-mediated Rejection in Donor Specific Antibody Positive Kidney Transplant RecipientsTransplantation Direct, 2018
- Diagnosis and Management of Antibody-Mediated Rejection: Current Status and Novel ApproachesAmerican Journal of Transplantation, 2014
- The Plasma Creatinine Concentration Is Not an Accurate Reflection of the Glomerular Filtration Rate in Stable Renal Transplant Patients Receiving CyclosporineAmerican Journal of Kidney Diseases, 1987
- Limitations of Creatinine in Quantifying the Severity of Cyclosporine-Induced Chronic NephropathyAmerican Journal of Kidney Diseases, 1986